Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer

Trial ID #	NCT00326456; MITO-2
Phase	III
Drug Class	Chemotherapy, Chemotherapy, Chemotherapy
Drug Name	Carboplatin, Liposomal doxorubicin, Paclitaxel
Alternate Drug Names	Paraplatin, Novoplatinum, Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL
Drugs in Trial	Carboplatin, Liposomal doxorubicin, Paclitaxel
Eligible Participant	Newly diagnosed stage IC-IV ovarian cancer
Patients Enrolled	820
Therapy Setting	First-line
Study Design	Open-Label, Randomized
Endpoints	PFS, OS, evaluated per RECIST
Efficacy	CarboPt+Pac vs CarboPt+PLD: PFS: 16.8 vs 19.0 months, HR: 0.95 (0.81-1.13, p=0.58) OS: 53.2 vs 61.6 months, HR: 0.89 (0.72-1.12, p=0.32)
Clinically Significant Adverse Events	CarboPt+Pac vs CarboPt+PLD: Grade 3-4 AE: anemia (3 vs 10%), thrombocytopenia (7 vs 16%) All grades: Hair loss (63 vs 14%), diarrhea (12 vs 6%) neuropathy (47 vs 15%) skin toxicity (6 vs 21%), stomatitis (9 vs 18%)
Conclusion	No significant PFS or OS difference when paclitaxel or liposomal doxorubicin is added to carboplatin, but different toxicity profiles
Reference	Pignata S et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol (2011) 29(27):3628-35 https://www.ncbi.nlm.nih.gov/pubmed/21844495